Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) represent a significant class of medications primarily used in the management of type 2 diabetes mellitus (T2DM) and, increasingly, obesity [1-3]. This evidence concerns the gene GCG and type 2 diabetes mellitus.